Physician profile
Lauren Slakey Pointer
NPI 1609255231
$3,896.18
in general payments reported to CMS, 2019-2025
28 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $13.80 · 2022: $406 · 2023: $1,192 · 2024: $1,339 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215 · Education: $23.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.85 |
| Education | $23.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.91 | 2020-2025 | |
| Janssen Biotech, INC. | $314.88 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $252.51 | 2023-2024 | Zeposia |
| Pfizer INC. | $193.96 | 2023-2025 | |
| Genzyme Corporation | $191.24 | 2023-2025 | |
| Mauna Kea Technologies, INC. | $166.22 | 2022 | |
| Mallinckrodt Hospital Products INC. | $143.57 | 2023 | Terlivaz |
| Ardelyx, INC. | $124.56 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $117.04 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $102.46 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $95.28 | 2019 | |
| Shire North American Group INC | $91.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.98 | 2024-2025 | Entyvio |
| Fresenius Kabi USA, LLC | $55.59 | 2023-2024 | Idacio |
| Celltrion USA INC. | $54.63 | 2023-2024 | Vegzelma, Yuflyma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $51.41 | 2019 | |
| Evoke Pharma, INC. | $46.29 | 2023-2024 | Gimoti |
| Gilead Sciences, INC. | $44.72 | 2024-2025 | |
| Madrigal Pharmaceuticals | $24.00 | 2024 | Resmetirom |
| Ironwood Pharmaceuticals, INC | $23.81 | 2023 | Linzess |
| Teva Pharmaceuticals USA, INC. | $23.09 | 2024 | Simlandi |
| Braintree Laboratories, INC. | $20.72 | 2024 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $19.17 | 2025 | Iqirvo |
| Lilly USA, LLC | $19.07 | 2025 | Omvoh |
| Biocon Biologics INC | $18.47 | 2024 | Hulio |
| Astrazeneca Pharmaceuticals LP | $18.18 | 2023 | |
| Novo Nordisk INC | $18.12 | 2025 | Wegovy |
| Exact Sciences Corporation | $15.16 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Pointer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.